Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results

Filed Breakthrough Medicine Designation Application with Saudi FDA for QRX003 in Netherton Syndrome – Submitted Application to Japanese MHLW ...
Yahoo Finance

NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome

Patients, families, and clinicians share the reality of living with Netherton Syndrome, a rare genetic skin disease with no approved treatment, and the enduring hope for a cure ASHBURN, Va., Feb. 26, ...

Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program

Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for ...
Nasdaq

Quoin Pharmaceuticals Launches "Living with Netherton" Video Series on Rare Disease Day to Raise Awareness for Netherton Syndrome

Quoin Pharmaceuticals Ltd. announced the launch of its "Living with Netherton" video series, aimed at raising awareness about Netherton Syndrome, a poorly understood genetic disease. The first episode ...
Nasdaq

Quoin Pharmaceuticals Files Patent Application for QRX003 to Treat Netherton Syndrome and Other Rare Skin Conditions

Quoin Pharmaceuticals Ltd. has filed a U.S. patent application for new topical formulations aimed at treating several skin diseases, specifically Netherton Syndrome (NS) and Peeling Skin Syndrome. The ...
Reuters

Quoin Reports Clinically Meaningful Whole Body Response to QRX003 in Pediatric Netherton Syndrome; Second Patient Cleared for Dosing

Initial pediatric subject shows sustained benefit with QRX003; second patient approved for full-body treatment in ongoing Netherton syndrome study ASHBURN, VA, April 2, 2025 (EZ Newswire) -- Quoin ...
Business Insider

Quoin Pharmaceuticals Announces FDA Grants Fast Track Designation for QRX003 for the Treatment of Netherton Syndrome

— Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant unmet medical need — — QRX003 lotion (4%) currently being ...
Seeking Alpha

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome

ASHBURN, Va., May 20, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty pharmaceutical company focused on rare and orphan diseases ...

Azitra secures US patent for ATR-12 skin disease treatment program

Azitra (NYSE American: AZTR) on Wednesday it has been granted a U.S. patent covering its lead product candidate ATR-12, an engineered microbial therapy under development for Netherton syndrome. The ...
Business Wire

Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting

BRANFORD, Conn.--(BUSINESS WIRE)--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced ...
Business Wire

LifeMax Receives Fast Track Designation For LM-030 for the Treatment of Netherton Syndrome

REDWOOD CITY, Calif.--(BUSINESS WIRE)--LifeMax Laboratories, Inc. (“LifeMax”), a private company focused on developing first-in-class or best-in-class therapeutics for the treatment of orphan diseases ...
News Medical

Two common Staph bacteria living on human skin exacerbate Netherton syndrome

Netherton syndrome, a rare skin disease caused by a single genetic mutation, is exacerbated by the presence of two common Staphylococcal bacteria living on human skin, one of which was previously ...